Director · IRulya Therapeutics, Inc. · IRulya Therapeutics Inc. — Director Stock Option (Right to Buy)
Side
A
Value
—
Shares
17.0K
Price
—
Executed
Nov 9, 2026
Disclosed
Nov 12, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Nov 9 executedNov 12, 2026 disclosed
IRLA · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing+6 / 15
Disclosed 3 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
IRulya Therapeutics Inc. — Director Stock Option (Right to Buy)
Ticker
IRLA
Shares
17.0K
Price per share
$0
Execution date (reported)
Nov 9, 2026
Owned after transaction
17.0K shares
Days from execution to publication
3
What this establishes
Bonuccelli Catherine M. filed this Form 4 reporting a grant or award of IRLA on Nov 9, 2026. It became public on Nov 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Bonuccelli Catherine M.cik:0002159407
Issuer
IRulya Therapeutics, Inc.cik:0001662774
Revision history · 0
No field has changed since this record was first ingested.
